Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early arthritis remission-targeted strategy trial
NL-OMON25364Active, not recruiting
- Sponsor
- Amsterdam UMC
- Start
- Jul 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of methotrexate, adalimumab, 5-aminosalicylic acid + sulphasalazine, hydroxychloroquine and prednisone in rheumatoid arthritis (RA), oligoarthritis and polyarthritis (2 arms), sponsored by Amsterdam UMC. Primary endpoint: Progression of radiographic damage score after 2 years. Started Jul 2004; status: active, not recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)oligoarthritispolyarthritis
Beyond the preview
Go deeper on NL-OMON25364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25364.